SIL 204
Alternative Names: KRASG12D-LODER; siG12D-LODER; SIL-204Latest Information Update: 08 Oct 2024
Price :
$50 *
At a glance
- Originator Silenseed
- Developer Silexion Therapeutics
- Class Antineoplastics; Gene therapies
- Mechanism of Action KRAS protein modulators; Ras gene modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Pancreatic cancer
- Research Colorectal cancer
Most Recent Events
- 03 Oct 2024 Pharmacodynamics data from a preclinical trial in Pancreatic cancer released by Silexion Therapeutics
- 01 Oct 2024 Silexion Therapeutics plans a toxicological studies for SIL 204 in upcoming months in 2024
- 24 Sep 2024 Efficacy data from a phase II trial in Pancreatic cancer released by Silexion Therapeutics